Výsledky vyhledávání - "Takuya Sakashita"

Akademický článek

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceResearch in context

Autor: Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama

Publikováno v: EBioMedicine, Vol 41, Iss , Pp 105-119 (2019)

Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Althoug

Externí odkaz: https://doaj.org/article/3388d031dc2d42b8a7c61b1d850adc34

Zobrazit plný text záznamu

Akademický článek

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Publikováno v: EBioMedicine, Vol 3, Iss C, Pp 54-66 (2016)

The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%–5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clin

Externí odkaz: https://doaj.org/article/215f36b14450475ab604c452115456af

Zobrazit plný text záznamu

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK ‐rearranged non–small cell lung cancer

Autor: Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew‐Kee Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama

Publikováno v: Cancer Science. 113:3888-3900

The rearrangement of anaplastic lymphoma kinase (ALK) occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK-tyrosine kinase inhibitors (TKIs). For the treatment of patients with ALK-rearranged NSCLC, vario

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::454e4e55bad9e62b7ee1ecd6405d8fbd
https://doi.org/10.1111/cas.15529

Zobrazit plný text záznamu

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

Autor: Yasushi Okuno, Naoya Fujita, Tomoko Oh-hara, Ryohei Katayama, Takeshi Ishikawa, Makoto Nishio, Sumie Koike, Takuya Sakashita, Noriko Yanagitani, Makoto Maemondo, Keiichi Tamai, Biao Ma, Mitsugu Araki, Koutaroh Okada, Atsushi Horiike, Ryo Kanada, Kana Watanabe

Publikováno v: EBioMedicine

Background: Alectinib has shown a greater efficacy to ALK-rearranged NSCLCs in first-line setting; however, most patients relapse due to secondary mutations in ALK such as I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40e76839c101dace9c9b5aef42ab2dac
https://doi.org/10.1016/j.ebiom.2019.01.019

Zobrazit plný text záznamu

Correction to: Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis

Autor: Celine Miyazaki, Shingo Kato, Takuya Sakashita, Wonjoo Jung

Publikováno v: Advances in Therapy. 38:2248-2248

The prevalence of ulcerative colitis (UC) is increasing in Japan but recent disease burden estimates are unavailable. This study was conducted to explore the prescription pattern and to estimate the economic burden in Japanese patients with UC. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::584eb852b5848910e46f1a4f18ec6a14
https://doi.org/10.1007/s12325-021-01671-4

Zobrazit plný text záznamu

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

Publikováno v: EBioMedicine, Vol 3, Iss C, Pp 54-66 (2016)
EBioMedicine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde7360999d4c3e253b32c7bd4debb62

Zobrazit plný text záznamu

Abstract PR03: Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance

Autor: Noriko Yanagitani, Ryohei Katayama, Takuya Sakashita, Makoto Nishio, Naoya Fujita, Kengo Takeuchi

Publikováno v: Molecular Cancer Therapeutics. 14:PR03-PR03

Anaplastic lymphoma kinase (ALK) rearrangement, which was first identified in non-small cell lung cancer (NSCLC) in 2007, is observed in 3%-5% of non-small-cell lung cancer (NSCLC) patients. For the treatment of ALK-rearranged non-small-cell lung can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e270bff67032caf1662f6ce487e9968
https://doi.org/10.1158/1535-7163.targ-15-pr03

Zobrazit plný text záznamu

Abstract 3590: Resistance mechanisms to ALK inhibitors

Autor: Ryohei Katayama, Alice T. Shaw, Makoto Nishio, Yasushi Okuno, Takuya Sakashita, Satoru Kitazono, Noriko Yanagitani, Naoya Fujita, Sumie Koike, Jeffrey A. Engelman

Publikováno v: Cancer Research. 75:3590-3590

Purpose: ALK-rearranged non-small cell lung cancer (NSCLC) was first reported in 2007. Approximately 3-5% of NSCLCs harbor an ALK gene rearrangement. The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::52becc37430d4f73029f8ed29b5dd482
https://doi.org/10.1158/1538-7445.am2015-3590

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání